JP2019523295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523295A5 JP2019523295A5 JP2019517209A JP2019517209A JP2019523295A5 JP 2019523295 A5 JP2019523295 A5 JP 2019523295A5 JP 2019517209 A JP2019517209 A JP 2019517209A JP 2019517209 A JP2019517209 A JP 2019517209A JP 2019523295 A5 JP2019523295 A5 JP 2019523295A5
- Authority
- JP
- Japan
- Prior art keywords
- myostatin
- pharmaceutical composition
- smn
- sma
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349596P | 2016-06-13 | 2016-06-13 | |
| US62/349,596 | 2016-06-13 | ||
| US201762470157P | 2017-03-10 | 2017-03-10 | |
| US62/470,157 | 2017-03-10 | ||
| US201762486934P | 2017-04-18 | 2017-04-18 | |
| US62/486,934 | 2017-04-18 | ||
| US201762511702P | 2017-05-26 | 2017-05-26 | |
| US62/511,702 | 2017-05-26 | ||
| US201762512254P | 2017-05-30 | 2017-05-30 | |
| US62/512,254 | 2017-05-30 | ||
| PCT/US2017/037332 WO2017218592A1 (en) | 2016-06-13 | 2017-06-13 | Use of myostatin inhibitors and combination therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000367A Division JP7161554B2 (ja) | 2016-06-13 | 2021-01-05 | ミオスタチン阻害剤の使用および併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523295A JP2019523295A (ja) | 2019-08-22 |
| JP2019523295A5 true JP2019523295A5 (enExample) | 2020-07-16 |
| JP6823167B2 JP6823167B2 (ja) | 2021-01-27 |
Family
ID=59093642
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517209A Active JP6823167B2 (ja) | 2016-06-13 | 2017-06-13 | ミオスタチン阻害剤の使用および併用療法 |
| JP2021000367A Active JP7161554B2 (ja) | 2016-06-13 | 2021-01-05 | ミオスタチン阻害剤の使用および併用療法 |
| JP2022064360A Active JP7344337B2 (ja) | 2016-06-13 | 2022-04-08 | ミオスタチン阻害剤の使用および併用療法 |
| JP2023142275A Pending JP2023164920A (ja) | 2016-06-13 | 2023-09-01 | ミオスタチン阻害剤の使用および併用療法 |
| JP2025136177A Pending JP2025183233A (ja) | 2016-06-13 | 2025-08-19 | ミオスタチン阻害剤の使用および併用療法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000367A Active JP7161554B2 (ja) | 2016-06-13 | 2021-01-05 | ミオスタチン阻害剤の使用および併用療法 |
| JP2022064360A Active JP7344337B2 (ja) | 2016-06-13 | 2022-04-08 | ミオスタチン阻害剤の使用および併用療法 |
| JP2023142275A Pending JP2023164920A (ja) | 2016-06-13 | 2023-09-01 | ミオスタチン阻害剤の使用および併用療法 |
| JP2025136177A Pending JP2025183233A (ja) | 2016-06-13 | 2025-08-19 | ミオスタチン阻害剤の使用および併用療法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10946036B2 (enExample) |
| EP (3) | EP3368069B1 (enExample) |
| JP (5) | JP6823167B2 (enExample) |
| KR (5) | KR20210082548A (enExample) |
| AU (4) | AU2017283546C1 (enExample) |
| CL (1) | CL2018003588A1 (enExample) |
| CY (1) | CY1123678T1 (enExample) |
| DK (2) | DK3368069T3 (enExample) |
| ES (1) | ES2830440T3 (enExample) |
| FI (1) | FI4218804T3 (enExample) |
| HR (2) | HRP20260160T1 (enExample) |
| HU (1) | HUE051480T2 (enExample) |
| IL (3) | IL301468A (enExample) |
| LT (2) | LT3368069T (enExample) |
| MY (2) | MY185614A (enExample) |
| NZ (3) | NZ789269A (enExample) |
| PE (1) | PE20190205A1 (enExample) |
| PT (2) | PT4218804T (enExample) |
| RS (2) | RS67857B1 (enExample) |
| SI (2) | SI3368069T1 (enExample) |
| SM (1) | SMT202000598T1 (enExample) |
| WO (1) | WO2017218592A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| WO2013125667A1 (ja) | 2012-02-24 | 2013-08-29 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| TWI636062B (zh) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
| US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| PT3922645T (pt) | 2015-09-15 | 2025-05-29 | Scholar Rock Inc | ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| KR20210082548A (ko) | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| MX2018014375A (es) * | 2016-06-17 | 2019-04-22 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y metodos de uso. |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| US11155611B2 (en) * | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
| WO2018187209A1 (en) * | 2017-04-03 | 2018-10-11 | Acceleron Pharma Inc. | Compositions and methods for treating spinal muscular atrophy |
| KR102636383B1 (ko) | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| WO2019170930A1 (es) * | 2018-03-09 | 2019-09-12 | Universitat De Lleida | Tratamiento para la atrofia muscular espinal |
| WO2019204369A1 (en) * | 2018-04-17 | 2019-10-24 | Applied Stemcell, Inc. | Compositions and methods for treating spinal muscular atrophy |
| PH12021551860A1 (en) | 2019-01-30 | 2022-05-16 | Scholar Rock Inc | Ltbp complex-specific inhibitors of tgfã and uses thereof |
| CN119320388A (zh) | 2019-02-04 | 2025-01-17 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7597744B2 (ja) * | 2019-06-19 | 2024-12-10 | エフ． ホフマン－ラ ロシュ アーゲー | デジタルバイオマーカー |
| WO2020254342A1 (en) * | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Digital biomarker |
| US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
| PL4232151T3 (pl) | 2020-10-26 | 2026-02-23 | Scholar Rock, Inc. | Zastosowanie przeciwciała przeciwko pro/latentnej miostatynie w leczeniu rdzeniowego zaniku mięśni |
| JP2024524159A (ja) | 2021-06-23 | 2024-07-05 | スカラー ロック インコーポレイテッド | 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤 |
| WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
| WO2023057404A1 (en) * | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
| CA3251441A1 (en) * | 2022-05-04 | 2023-11-09 | Scholar Rock, Inc. | USE OF A MYOSTATIN INHIBITOR FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2026008041A1 (zh) * | 2024-07-04 | 2026-01-08 | 江苏恒瑞医药股份有限公司 | 特异性结合潜伏肌生长抑制素的抗原结合分子及其医药用途 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| WO1996001845A1 (en) | 1994-07-08 | 1996-01-25 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| ATE364632T1 (de) | 2001-10-05 | 2007-07-15 | Affimed Therapeutics Ag | Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| PL218992B1 (pl) | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
| EP1578928B1 (en) | 2002-09-16 | 2010-03-17 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| ATE472556T1 (de) | 2002-12-02 | 2010-07-15 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| CN1902221A (zh) | 2003-12-31 | 2007-01-24 | 先灵-普劳有限公司 | 基于中和表位的生长增强疫苗 |
| US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7316998B2 (en) | 2004-05-27 | 2008-01-08 | Acceleron Pharma Inc. | Cerberus/Coco derivatives and uses thereof |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| EP1877075A4 (en) | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| WO2008030367A2 (en) * | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| ES2569365T3 (es) | 2006-11-29 | 2016-05-10 | Nationwide Children's Hospital | Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular |
| CN101663047B (zh) | 2007-02-23 | 2014-07-09 | 纽约哥伦比亚大学理事会 | 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法 |
| KR101531722B1 (ko) | 2007-03-30 | 2015-06-25 | 메르크 파텐트 게엠베하 | 음성 광학 분산도를 갖는 복굴절층 |
| WO2008127722A1 (en) | 2007-04-12 | 2008-10-23 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| JP2010529024A (ja) | 2007-06-01 | 2010-08-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| CA2993053A1 (en) | 2009-04-27 | 2010-11-04 | Novartis Ag | Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth |
| JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ， インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
| WO2011110642A2 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CA2808382A1 (en) | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US20130178454A1 (en) * | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150284455A1 (en) | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| BR112015027336A2 (pt) * | 2013-05-01 | 2017-09-26 | Genzyme Corp | composições e processos para tratamento de atrofia muscular espinhal |
| HUE052232T2 (hu) | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Készítmények és eljárások növekedési faktor modulálására |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| CA2929574A1 (en) | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| WO2016168613A1 (en) * | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| PT3922645T (pt) | 2015-09-15 | 2025-05-29 | Scholar Rock Inc | ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| KR20210082548A (ko) | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
-
2017
- 2017-06-13 KR KR1020217019817A patent/KR20210082548A/ko not_active Ceased
- 2017-06-13 PE PE2018003207A patent/PE20190205A1/es unknown
- 2017-06-13 RS RS20260217A patent/RS67857B1/sr unknown
- 2017-06-13 SI SI201730485T patent/SI3368069T1/sl unknown
- 2017-06-13 KR KR1020237005734A patent/KR20230028813A/ko not_active Ceased
- 2017-06-13 FI FIEP23157280.1T patent/FI4218804T3/fi active
- 2017-06-13 SM SM20200598T patent/SMT202000598T1/it unknown
- 2017-06-13 NZ NZ789269A patent/NZ789269A/en unknown
- 2017-06-13 NZ NZ789250A patent/NZ789250A/en unknown
- 2017-06-13 HR HRP20260160TT patent/HRP20260160T1/hr unknown
- 2017-06-13 DK DK17732001.7T patent/DK3368069T3/da active
- 2017-06-13 IL IL301468A patent/IL301468A/en unknown
- 2017-06-13 EP EP17732001.7A patent/EP3368069B1/en active Active
- 2017-06-13 PT PT231572801T patent/PT4218804T/pt unknown
- 2017-06-13 HU HUE17732001A patent/HUE051480T2/hu unknown
- 2017-06-13 NZ NZ789268A patent/NZ789268A/en unknown
- 2017-06-13 DK DK23157280.1T patent/DK4218804T3/da active
- 2017-06-13 SI SI201731653T patent/SI4218804T1/sl unknown
- 2017-06-13 KR KR1020237042111A patent/KR20230169484A/ko not_active Ceased
- 2017-06-13 HR HRP20201764TT patent/HRP20201764T1/hr unknown
- 2017-06-13 PT PT177320017T patent/PT3368069T/pt unknown
- 2017-06-13 KR KR1020267004587A patent/KR20260028184A/ko active Pending
- 2017-06-13 IL IL326484A patent/IL326484A/en unknown
- 2017-06-13 EP EP23157280.1A patent/EP4218804B1/en active Active
- 2017-06-13 KR KR1020197000822A patent/KR102271635B1/ko active Active
- 2017-06-13 LT LTEP17732001.7T patent/LT3368069T/lt unknown
- 2017-06-13 MY MYPI2018002494A patent/MY185614A/en unknown
- 2017-06-13 AU AU2017283546A patent/AU2017283546C1/en active Active
- 2017-06-13 RS RS20201327A patent/RS61090B1/sr unknown
- 2017-06-13 US US16/308,007 patent/US10946036B2/en active Active
- 2017-06-13 MY MYPI2020004682A patent/MY199499A/en unknown
- 2017-06-13 EP EP20179533.3A patent/EP3785728A3/en active Pending
- 2017-06-13 ES ES17732001T patent/ES2830440T3/es active Active
- 2017-06-13 WO PCT/US2017/037332 patent/WO2017218592A1/en not_active Ceased
- 2017-06-13 JP JP2019517209A patent/JP6823167B2/ja active Active
- 2017-06-13 LT LTEP23157280.1T patent/LT4218804T/lt unknown
-
2018
- 2018-12-05 IL IL263510A patent/IL263510A/en unknown
- 2018-12-13 CL CL2018003588A patent/CL2018003588A1/es unknown
-
2020
- 2020-07-27 AU AU2020210134A patent/AU2020210134B2/en active Active
- 2020-11-03 CY CY20201101038T patent/CY1123678T1/el unknown
-
2021
- 2021-01-05 JP JP2021000367A patent/JP7161554B2/ja active Active
- 2021-02-03 US US17/248,700 patent/US20210283166A1/en active Pending
- 2021-11-04 AU AU2021261907A patent/AU2021261907B2/en active Active
-
2022
- 2022-04-08 JP JP2022064360A patent/JP7344337B2/ja active Active
-
2023
- 2023-09-01 JP JP2023142275A patent/JP2023164920A/ja active Pending
-
2024
- 2024-05-22 AU AU2024203412A patent/AU2024203412A1/en active Pending
-
2025
- 2025-08-19 JP JP2025136177A patent/JP2025183233A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201764T1 (hr) | Upotreba inhibitora miostatina i kombinacijske terapije | |
| JP7288927B2 (ja) | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用 | |
| RU2017120437A (ru) | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2011506483A5 (enExample) | ||
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| JP2025102888A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2015503909A5 (enExample) | ||
| JP2014525465A5 (enExample) | ||
| JP2018512435A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2020502261A5 (enExample) | ||
| JP2022525164A5 (enExample) | ||
| IL276896B2 (en) | Methods of treating crohn's disease with anti-il23 specific antibody | |
| JP2023138982A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法 | |
| JP2025514978A5 (enExample) | ||
| JP2021532176A5 (enExample) | ||
| JP2021530697A5 (enExample) | ||
| JP2021523881A5 (enExample) | ||
| TW202126329A (zh) | 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法 | |
| JP2024528877A5 (enExample) | ||
| JP2021533142A5 (enExample) | ||
| JP2023544620A5 (enExample) |